FDA Warns Novo Nordisk Over Unreported GLP-1 Deaths

Affiliate Disclosure: The GLP-1 Daily may earn a commission from links on this page. This does not influence our editorial coverage. See our full affiliate disclosure.

Quick Answer

The FDA issued a warning letter to Novo Nordisk on March 5, 2026, citing "serious violations" in reporting adverse events related to semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda, Victoza).
Three patient deaths went unreported to the FDA, including one suicide and two additional fatalities — along with at least 10 other serious adverse events the company failed to document.
The FDA did not say GLP-1 medications caused these deaths. The warning focuses on Novo Nordisk's failure to follow legally required safety reporting procedures, not on medication safety itself.
Patients currently taking Ozempic or Wegovy should not stop their medication without consulting their doctor. No changes to prescribing guidelines have been made as a result of this letter.

The U.S. Food and Drug Administration has sent a formal warning letter to Novo Nordisk, the Danish pharmaceutical giant behind some of the world's most prescribed GLP-1 receptor agonist medications, for failing to report patient deaths and serious adverse events to the agency within the legally required time frame.

The warning letter, dated March 5, 2026, and made public on March 10, stems from an FDA inspection of Novo Nordisk's U.S. headquarters in Plainsboro, New Jersey, conducted between January 13 and February 7, 2025. Inspectors found what the agency described as "serious violations" of post-marketing adverse drug experience (PADE) reporting requirements under Section 505(k) of the Federal Food, Drug, and Cosmetic Act and Title 21 of the Code of Federal Regulations (21 CFR 314.80).

The revelations have sent ripples through the GLP-1 medication market, raising questions about pharmaceutical companies' obligations to patients and regulators — even as medical experts emphasize that the warning does not change the safety profile of semaglutide or liraglutide themselves.

What the FDA Found: Three Deaths and Systemic Reporting Failures

The FDA's warning letter details a troubling pattern of lapses in Novo Nordisk's adverse event reporting systems. At the center of the findings are three patient deaths that the company either failed to report or failed to investigate adequately.

The Unreported Cases

Case 1 — Suicide linked to semaglutide: A physician reported to Novo Nordisk that a patient taking semaglutide experienced depression and subsequently died by suicide. According to the FDA, Novo Nordisk "failed to promptly investigate" the case, did not document any attempt to obtain additional information from the reporting physician, and — as of the date the warning letter was issued — had still not submitted the case to the FDA. Under federal regulations, drug manufacturers are required to report serious and unexpected adverse events within 15 calendar days of becoming aware of them.

Case 2 — Patient death dated January 30, 2024: A male patient who had received semaglutide died, but Novo Nordisk failed to capture a patient identifier and did not submit the required report to the FDA. The specific cause of death in this case was not detailed in the public warning letter.

Case 3 — Patient death dated December 20, 2024: A second patient death occurred and went unreported within the required time frame. Additional details about this case remain limited in the publicly available documentation.

Beyond the Deaths

The unreported deaths were not isolated incidents. The FDA's inspection revealed broader, systemic problems in how Novo Nordisk handled adverse event reports:

A disabling stroke: A patient taking liraglutide (the active ingredient in Saxenda and Victoza) experienced a stroke that left them disabled. This event was not properly reported to the FDA.
Suicidal ideation: A consumer reported experiencing suicidal thoughts while taking semaglutide. This report was not adequately investigated or filed.
At least 10 additional serious events: Investigators found that Novo Nordisk failed to file Individual Case Safety Reports (ICSRs) — the standardized documentation the FDA requires when drug toxicity or other product-related problems are identified — for at least 10 serious and listed adverse events.

The FDA also determined that Novo Nordisk failed to develop adequate written procedures for the "surveillance, receipt, evaluation, and reporting of postmarketing adverse drug experiences," a fundamental requirement under 21 CFR 314.80(b).

If you're currently taking a GLP-1 medication and want to understand the full range of known side effects, our complete GLP-1 side effects guide covers what clinical trials and post-market data have established.

Why Adverse Event Reporting Matters

To understand the significance of this warning letter, it helps to understand how the drug safety reporting system works — and why failures in it are taken so seriously by regulators.

The Post-Marketing Surveillance System

When the FDA approves a medication, clinical trials have typically involved thousands of participants. But once a drug reaches the market, millions of people may take it — often including populations that were underrepresented in trials, such as older adults, people with multiple chronic conditions, or those taking several medications simultaneously.

Post-marketing surveillance exists to catch safety signals that clinical trials may have been too small or too short to detect. Drug manufacturers are legally required to:

Collect reports of adverse events from healthcare providers, patients, and consumers
Investigate each report promptly to assess its significance
Evaluate whether the event represents a new safety signal
Report serious and unexpected events to the FDA within 15 calendar days
File periodic safety reports summarizing all adverse events

This system depends on pharmaceutical companies acting as responsible intermediaries between patients and regulators. When a company fails to report adverse events, the FDA loses visibility into potential safety problems — and patients may not receive updated safety information they need.

The Scale of GLP-1 Usage

The stakes are particularly high for GLP-1 medications given their enormous and rapidly growing patient population. As of early 2026, an estimated 15.5 million Americans have been prescribed a GLP-1 receptor agonist, according to IQVIA prescription data. Semaglutide alone generated over $18 billion in U.S. revenue for Novo Nordisk in 2025, making it one of the best-selling pharmaceutical products in history.

With that many patients taking these medications, robust adverse event reporting isn't just a regulatory formality — it's an essential public health safeguard.

Novo Nordisk's Response

Novo Nordisk has acknowledged the warning letter and indicated it intends to cooperate with the FDA's demands.

"Novo Nordisk takes PADE reporting requirements seriously and we plan to address the requests in the Warning Letter expeditiously and holistically," said Anna Windle, the company's head of Clinical Development, Medical and Regulatory Affairs, in a public statement.

The company noted that it had already submitted multiple responses to the FDA between March 2025 and January 2026, describing corrective actions it had taken, including:

Revising internal procedures for adverse event intake and reporting
Conducting retrospective reviews of previously received cases
Transitioning safety case intake to dedicated, insourced patient safety agents (rather than relying on outsourced call centers)

However, the FDA deemed these responses inadequate. In issuing the formal warning letter, the agency stated that Novo Nordisk "did not provide sufficient details to determine whether the actions would prevent similar violations in the future."

The FDA has given Novo Nordisk 15 business days from the date of the letter to respond with a detailed plan outlining specific steps to prevent future violations.

What This Tells Us

The timeline here is notable. The FDA inspection took place in early 2025, and Novo Nordisk has been submitting corrective action plans for nearly a year. The fact that the FDA escalated to a formal warning letter — one of the agency's stronger enforcement tools — suggests the agency was not satisfied with the pace or substance of the company's remediation efforts.

Warning letters are public documents that can carry significant reputational and financial consequences for pharmaceutical companies. They can also serve as a precursor to more severe enforcement actions, including consent decrees, product seizures, or injunctions, if the underlying violations are not resolved.

What This Means for Current GLP-1 Patients

If you're currently taking Ozempic, Wegovy, or another GLP-1 medication, here's what you need to know.

The Medications Are Not Being Recalled

The FDA's warning letter is a regulatory action directed at Novo Nordisk's reporting procedures. It is not a safety recall, and it does not change the approved status of any GLP-1 medication. Ozempic and Wegovy remain FDA-approved for their indicated uses (type 2 diabetes management and chronic weight management, respectively).

The FDA Has Not Established Causation

A critical point that has been underreported in some coverage: the FDA explicitly did not state that semaglutide or liraglutide caused the deaths or serious adverse events cited in the warning letter. The issue is that Novo Nordisk failed to report these events so they could be properly investigated.

In fact, the FDA conducted a separate evaluation of whether GLP-1 medications are linked to suicidality and concluded that the available evidence does not support a causal connection. This evaluation was referenced in several news reports covering the warning letter.

Do Not Stop Your Medication Without Medical Guidance

Medical experts have been clear in their messaging: patients should not stop taking their prescribed GLP-1 medications based on this warning letter alone. Abruptly discontinuing diabetes or weight management medications can have serious health consequences, including blood sugar spikes, rapid weight regain, and other metabolic disruptions.

If you have concerns, schedule a conversation with your prescribing physician to discuss your individual risk profile.

For a detailed comparison of the GLP-1 medications currently available, including their safety profiles and costs, see our guides on the best GLP-1 medications for 2026 and semaglutide vs. tirzepatide.

The Broader Context: GLP-1 Safety Under the Microscope

This warning letter arrives during a period of intense scrutiny for the GLP-1 drug class. While the medications have shown strong efficacy for both diabetes management and weight loss, their rapid adoption has raised questions about long-term safety that the medical community is still working to answer.

Known Side Effects and Ongoing Monitoring

The most common side effects of GLP-1 receptor agonists — nausea, vomiting, diarrhea, and constipation — are well-documented and typically diminish over time. More serious but rarer events, including pancreatitis, gastroparesis, and thyroid C-cell tumors (observed in animal studies), are included in the medications' prescribing labels.

The question of whether GLP-1 medications carry psychiatric risks, including depression and suicidal ideation, has been a particular area of investigation. The European Medicines Agency (EMA) launched a review of this question in 2023, and the FDA has been monitoring reports as well. To date, neither agency has established a causal link, but the unreported suicide case in the FDA's warning letter underscores why complete reporting is so important — it's difficult to rule out a connection when cases aren't being submitted for analysis.

Industry-Wide Implications

The FDA's action against Novo Nordisk may have implications beyond a single company. Eli Lilly, which manufactures the competing GLP-1 medication tirzepatide (Mounjaro, Zepbound), and other pharmaceutical companies in the space will likely face heightened regulatory scrutiny of their own adverse event reporting practices.

Pharmaceutical industry analysts have noted that the FDA has been increasingly aggressive in enforcing post-marketing surveillance requirements across the industry, particularly for high-volume medications where even small percentage risks can translate into large absolute numbers of affected patients.

Stock Market Reaction

Novo Nordisk's stock price declined following the public release of the warning letter, reflecting investor concerns about both the reputational damage and the potential for further regulatory action. The company's shares had already been under pressure due to competitive dynamics in the GLP-1 market, and this development added to the uncertainty.

For patients concerned about medication costs amid market changes, our GLP-1 cost guide tracks current pricing and coverage options.

What Happens Next

The regulatory process following a warning letter follows a structured path:

Immediate Timeline

15 business days: Novo Nordisk must submit a detailed response to the FDA outlining specific corrective actions and providing evidence that those actions will prevent future violations.
FDA review: The agency will evaluate the response and determine whether the proposed corrective actions are adequate.
Follow-up inspection: The FDA may conduct a follow-up inspection to verify that corrective actions have been implemented.

Potential Consequences

If Novo Nordisk fails to adequately address the violations, the FDA has several escalation options:

Consent decree: A court-ordered agreement requiring specific compliance actions, often with ongoing FDA oversight
Civil monetary penalties: Financial penalties for continued noncompliance
Product seizure or injunction: In extreme cases, the FDA can seek court orders to seize products or halt manufacturing — though this outcome is highly unlikely for a widely used medication with established efficacy
Criminal prosecution: Reserved for the most egregious cases involving fraud or willful misconduct

Most pharmaceutical companies resolve warning letter issues through corrective action plans and follow-up inspections. Escalation beyond the warning letter stage is relatively uncommon, particularly for paperwork and procedural violations rather than manufacturing defects.

Congressional Interest

The warning letter has also attracted attention from members of Congress who have been pushing for greater pharmaceutical industry accountability. Several lawmakers have cited the Novo Nordisk case as evidence that the FDA needs stronger enforcement authority and that pharmaceutical companies require more robust oversight, particularly as blockbuster medications like GLP-1 drugs reach tens of millions of patients.

How to Protect Yourself as a GLP-1 Patient

While this warning letter is primarily a regulatory matter between the FDA and Novo Nordisk, there are practical steps patients can take to be proactive about their safety:

Report Side Effects Directly

You don't have to rely on your pharmaceutical company to report adverse events. Patients and healthcare providers can report side effects directly to the FDA through:

MedWatch: The FDA's safety reporting portal at fda.gov/medwatch
Phone: 1-800-FDA-1088
Your healthcare provider: Ask your doctor to submit an adverse event report on your behalf

Keep Detailed Records

Maintain a log of any side effects you experience, including:

When the side effect started relative to your medication dose
Severity and duration
Any other medications you're taking
Whether the side effect resolved on its own or required treatment

Stay Informed

Follow updates from the FDA and your healthcare provider. If the agency determines that new safety information needs to be added to medication labels, your doctor will be notified through official channels.

Ask Questions at Your Next Appointment

Bring up the warning letter with your prescribing physician at your next visit. Key questions to ask:

Are there any new safety concerns I should be aware of?
Should my monitoring schedule change?
What symptoms should prompt me to seek immediate medical attention?

Frequently Asked Questions

Is the FDA recalling Ozempic or Wegovy because of this warning letter?

No. The FDA's warning letter is a regulatory enforcement action directed at Novo Nordisk's adverse event reporting practices. It is not a product recall, and it does not change the approval status of any GLP-1 medication. Ozempic and Wegovy remain FDA-approved and available by prescription for their indicated uses — type 2 diabetes management and chronic weight management, respectively.

Did the FDA say that Ozempic or Wegovy caused the reported deaths?

No. The FDA explicitly did not establish a causal connection between semaglutide and the deaths cited in the warning letter. The agency's concern is that Novo Nordisk failed to report these events within the legally required time frame, which prevents proper investigation. A separate FDA evaluation found no evidence of a causal link between GLP-1 medications and suicidality.

Should I stop taking my GLP-1 medication after reading about this warning letter?

You should not stop taking any prescribed medication without consulting your healthcare provider. Medical experts have emphasized that abruptly discontinuing GLP-1 medications can lead to serious health consequences, including blood sugar instability for diabetes patients and rapid weight regain. If you have concerns, schedule an appointment with your prescribing physician to discuss your individual situation and risk factors.

What is Novo Nordisk doing to fix the problem?

Novo Nordisk has stated that it "takes PADE reporting requirements seriously" and plans to address the FDA's concerns "expeditiously and holistically." The company has already taken some corrective steps, including revising internal procedures, conducting retrospective case reviews, and transitioning safety case intake to dedicated in-house patient safety agents. However, the FDA has deemed these actions insufficient so far and has given the company 15 business days to provide a more detailed corrective action plan.

Does this warning letter affect other GLP-1 medications like Mounjaro or Zepbound?

The warning letter is specific to Novo Nordisk and its medications (semaglutide and liraglutide). It does not directly affect Eli Lilly's tirzepatide products (Mounjaro and Zepbound) or other GLP-1 medications from different manufacturers. However, the increased regulatory scrutiny may lead to closer examination of adverse event reporting practices across the entire GLP-1 drug class and the pharmaceutical industry more broadly.

This article is for informational purposes only and does not constitute medical advice. GLP-1 receptor agonists are prescription medications that should only be used under the supervision of a qualified healthcare provider. If you are experiencing side effects from any medication, contact your healthcare provider immediately. If you are experiencing suicidal thoughts, call or text 988 to reach the Suicide and Crisis Lifeline, available 24/7.

-- The GLP-1 Daily Team